EP3973550B1 - Composition d'ionogel peptidique, procédés et utilisations de celle-ci - Google Patents

Composition d'ionogel peptidique, procédés et utilisations de celle-ci Download PDF

Info

Publication number
EP3973550B1
EP3973550B1 EP20732663.8A EP20732663A EP3973550B1 EP 3973550 B1 EP3973550 B1 EP 3973550B1 EP 20732663 A EP20732663 A EP 20732663A EP 3973550 B1 EP3973550 B1 EP 3973550B1
Authority
EP
European Patent Office
Prior art keywords
ionogel
tripeptide
previous
phenylalanine
ionogels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP20732663.8A
Other languages
German (de)
English (en)
Other versions
EP3973550C0 (fr
EP3973550A1 (fr
Inventor
Ana Cecília AFONSO ROQUE
Carina Alexandra MARQUES ESTEVES
Rein VINCENT ULIJN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NovaIdFct Associacao Para A Inovacao E Desenvolvimento Da Fct
Universidade Nova de Lisboa
Research Foundation of City University of New York
Original Assignee
NovaIdFct Associacao Para A Inovacao E Desenvolvimento Da Fct
Universidade Nova de Lisboa
Research Foundation of City University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NovaIdFct Associacao Para A Inovacao E Desenvolvimento Da Fct, Universidade Nova de Lisboa, Research Foundation of City University of New York filed Critical NovaIdFct Associacao Para A Inovacao E Desenvolvimento Da Fct
Publication of EP3973550A1 publication Critical patent/EP3973550A1/fr
Application granted granted Critical
Publication of EP3973550C0 publication Critical patent/EP3973550C0/fr
Publication of EP3973550B1 publication Critical patent/EP3973550B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01B—CABLES; CONDUCTORS; INSULATORS; SELECTION OF MATERIALS FOR THEIR CONDUCTIVE, INSULATING OR DIELECTRIC PROPERTIES
    • H01B1/00—Conductors or conductive bodies characterised by the conductive materials; Selection of materials as conductors
    • H01B1/06—Conductors or conductive bodies characterised by the conductive materials; Selection of materials as conductors mainly consisting of other non-metallic substances
    • H01B1/12—Conductors or conductive bodies characterised by the conductive materials; Selection of materials as conductors mainly consisting of other non-metallic substances organic substances
    • H01B1/122—Ionic conductors

Definitions

  • the present disclosure relates to unprotected tripeptide ionogel compositions, respective production processes and characterization with application in a variety of technological fields.
  • Hydrogels are materials typically composed of more than 90% (w/w) of water. Peptides can self-assemble into hydrogels, representing a promising class of soft biomaterials that has received increasing attention during the last decades.
  • the process of peptide self-organization occurs at a molecular level in a 'bottom-up' approach where the simplest biomolecules, such as peptides or amino acids, interact with each other in aqueous solutions in a coordinated manner. In this process, one-dimensional peptide aggregates evolve to form fibrils that coil into larger fibres, crosslinking to form a gel.
  • supramolecular self-assembled gels are highly dynamic structures where the molecular self-assembly process, mediated by non-covalent interactions such as hydrogen bonds, ionic bonds (electrostatic interactions), hydrophobic or van de Waals interactions, can be triggered and reversed by several external stimuli, such as pH, temperature, ionic strength, or gelator concentration [1-4].
  • Several protected and unprotected short peptides (2 to 4 amino acids) have been shown to form hydrogels [5,6]. The capability of hydrogelation of unprotected peptides at physiological pH has also been previously reported [7-9].
  • hydrogels weakness is the low stability in non-aqueous environments. When exposed to air, for example at ambient room conditions, hydrogels rapidly lose moisture, shrink and turn brittle due to water evaporation. On the other hand, to turn hydrogels into conductive materials there is usually the need to incorporate dopants in the hydrogel formulation [10].
  • Ionic liquids are molten salts composed by at least one organic salt of composition X + and Y - , wherein X + represents the cation of the salt and Y - represents the anion of the salt.
  • the melting point of ionic liquids is below 100°C, and they show very low volatility.
  • Ionic liquids are designer solvents in the sense that the anion and cation can be varied and tuned to different purposes.
  • Ionic liquids are considered green solvents with very interesting properties, namely high ionic conductivity, large electrochemical window, low vapour pressure, excellent thermal, electrochemical and chemical stability, non-flammability, non-toxicity, biocompatibility and biodegradability.
  • ionogels retain the interesting features of the ionic liquids they are composed of, but the immobilization of ionic liquids to yield advanced functional materials is still challenging [11]. The entrapment of ionic liquids within biological matrices following a designed "bottom-up" approach is challenging and largely unexplored.
  • Low molecular weight gelators are small molecules with molecular weight less than 2000 Da.
  • the physical gelation of low-molecular- weight compounds results from non-covalent bonds, such as hydrogen bonds.
  • gelator molecules are first self-assembled, producing fibrous assemblies. Then, these fibrous assemblies form a three-dimensional network structure, and gelation occurs by trapping solvent in the networks.
  • Short peptide sequences including unprotected tripeptides, fall within this category of LMWGs.
  • the developed ionogels were exploited as adsorbing agents in environmental clean-up and as templates in the synthesis of TiO 2 nanoparticles.
  • Other examples report the development of conductive, soft, elastic ionogels with countless applications in chemocatalysis and biocatalysis; metal recovery; pharmaceuticals; electrochemical devices such batteries, capacitors and solar cells; electrolytes; semi-solid lubricants; magnetorheological fluids and electrochemical devices; adsorbing agents; or solid electrolytes [14-18].
  • ionogels made by the gelation of ionic liquids by LMWGs, there is no report on the employment of unprotected short peptide sequences as ionogelators.
  • the present disclosure relates to a peptide ionogel composition (or formulation), wherein unprotected tripeptides are used as gelators.
  • the tripeptide ionogels result from the gelation of ionic liquids with unprotected tripeptides that present self-assembly propensity.
  • protected peptides with self-assembly propensity are those chemically modified with functional moieties at one or more different sites, namely the C-terminus, the N-terminus or at the amino acid side chains.
  • the protecting groups used for the modification have self-assembling properties usually due to the hydrophobicity and aromaticity, and include the 9-fluorenylmethyloxycarbonyl (Fmoc) group, or any groups containing aromatic tails, naphtyls, lipids, fatty acids, cyclic compounds, sugars, carbamide, or aliphatic tail-moieties [19].
  • Unprotected peptides are those that are not modified at the C-terminus, N-terminus or side chains with protecting groups presenting self-assembling propensity, as listed above.
  • the tripeptide ionogels here described are supramolecular peptide assemblies in ionic liquids. They are stable at ambient conditions, have thermal, electrochemical and chemical stability in a wide range of temperature and humidity conditions, are conducting, soft, self-healing, thermoreversible, have a large electrochemical window, are non-flammable, non-toxic, biocompatible and biodegradable materials. These materials can further encapsulate other stimuli-responsive elements, as for example optical probes made of liquid crystals, including liquid crystals presenting nematic, smectic or chiral phases.
  • the major advantages and unique properties of the formulations and production methods of tripeptide ionogels described in the present disclosure are:
  • An aspect of the present disclosure relates to an ionogel composition
  • an ionogel composition comprising:
  • a gelator is a substance capable of forming a gel.
  • an ionogelator is defined as a molecule responsible for the gelation of ionic liquids. Gelation is defined as a process in which the immobilization of a given solvent leads to the formation of soft materials.
  • the tripeptide concentration ranges from 10 - 700 mM.
  • the tripeptide concentration ranges from 20 - 600 mM, preferably 100 - 400 mM, more preferably 50 - 400 mM.
  • the tripeptide concentration ranges from 20 -200 mM, preferably 20 - 100 mM.
  • the unprotected tripeptides have an amide at the C-terminal, preferably Aspartic acid-Phenylalanine-Tyrosine, and Tyrosine-Phenylalanine-Aspartic acid peptides.
  • the unprotected tripeptides comprise a molecular weight equal or inferior to 2000 g/mol, preferably between 270-540 g/mol.
  • the ionic liquid concentrations range from 20-98 % (w/w).
  • the ionic liquid is selected from phosphate-containing ionic liquids, chloride-containing ionic liquids, dicyanamide-containing ionic liquids, quaternary ammonium salts, or mixtures thereof.
  • the imidazolium-based ionic liquids are selected from a list comprising: 1-butyl-3-methylimidazolium dicyanamide, 1-ethyl-3-methylimidazolium dicyanamide, 1-butyl-3-methylimidazolium chloride, 1-ethyl-3-methylimidazolium chloride, 1 or mixtures thereof.
  • ammonium-based ionic liquids are selected from a list comprising: choline chloride, choline hydroxide, choline phosphate buffer, 2-hydroxyethylammonium formate, choline dihydrogenphoshate, dicholine monohydrogenphosphate, or mixtures thereof.
  • the choline phosphate ionic liquid buffer system (choline phosphate buffer) is produced by the addition in equimolar amounts of the ionic liquids choline dihydrogenphosphate and dicholine monohydrogenphosphate.
  • the water content of choline phosphate buffer ranges from 16-22% wt.
  • the tripeptides ionogelation is triggered by changes on the pH, increasing the pH to 7-9, preferentially 7.5-8.5.
  • the pH is increased by addition of sodium hydroxide, choline hydroxide or 1-butyl-3-methylimidazolium hydroxide.
  • the tripeptides ionogelation is triggered by changes on the temperature or a buffer composition.
  • the ionogels' water concentration is below 90% (w/w), preferably between 2-75% (w/w).
  • the molecular self-assembly of the tripeptide occurs by non-covalent interactions such as hydrogen bonding, hydrophobic, electrostatic, van der Walls, and ⁇ -stacking, ⁇ -cation, ⁇ -sulphur, dipole-dipole, ionic, or metal-chelating interactions.
  • the ionogel composition may further comprise an additive selected from the following list: citric acid, tartaric acid, ascorbic acid, glucose, sucrose, xylose, arginine, histidine, proline, urea, sorbitol, xylitol, glycerol, monoethylene glycol, menthol, lactic acid, betain, or mixtures thereof.
  • an additive selected from the following list: citric acid, tartaric acid, ascorbic acid, glucose, sucrose, xylose, arginine, histidine, proline, urea, sorbitol, xylitol, glycerol, monoethylene glycol, menthol, lactic acid, betain, or mixtures thereof.
  • ionogel composition might comprise choline dihydrogenphosphate:citric acid, choline dihydrogenphosphate:tartaric acid, choline dihydrogenphosphate:ascorbic acid, choline dihydrogenphosphate:glucose, choline dihydrogenphosphate:sucrose, choline dihydrogenphosphate:xylose; choline dihydrogenphosphate:arginine; choline dihydrogenphosphate:histidine; choline dihydrogenphosphate:proline; choline dihydrogenphosphate:sorbitol; choline dihydrogenphosphate:xylitol; choline dihydrogenphosphate:monoethylene glycol; choline dihydrogenphosphate:lactic acid; dicholine monohydrogenphosphate: citric acid; dicholine monohydrogenphosphate:tartaric acid; dicholine monohydrogenphosphate:ascorbic acid, dicholine monohydrogenphosphate:glucose, dicholine monohydrogenphosphate:
  • the ionogel is stable at ambient conditions (temperature - 18-27°C, pressure - atmospheric, 1013.25hPa, relative humidity - 30-80%).
  • the ionogel is soft, self-healable, thermoreversible, stimuli-responsive, non-flammable, non-toxic, biocompatible and biodegradable.
  • the ionogel composition may further comprise a stimuli-responsive component.
  • the stimuli-responsive component is a liquid crystal.
  • the ionogel composition may be obtainable by moulding, casting, spin-coating, film coating, spinning, electrospinning, microfluidic, 3D-printing, ink-jet printing, patterning or metal deposition method.
  • Another aspect of the present disclosure relates to a disc, film, fiber, sphere, cube, mesh, channel or patterned structure comprising the ionogel composition of the present disclosure.
  • Another aspect of the present disclosure relates to an article comprising the ionogel composition of the present disclosure.
  • the article is a sensing device, electronic device, opto-electronic device, flexible device, wearable device, conducting device, coating material, electrochemical device, electrolyte, semi-solid lubricant, adsorbent agent; pharmaceutical formulation, food product, or cosmetic product.
  • Another aspect of the present disclosure relates to use of the ionogel composition described in the present disclosure for additive manufacturing, chemocatalysis or biocatalysis, encapsulation, drug delivery and/or cell assays.
  • Another aspect of the present disclosure further relates to a kit or a reagent comprising the ionogel composition of the present disclosure.
  • Another aspect of the present disclosure further relates to a method for preparing the ionogel composition of the present disclosure, comprising the following steps:
  • the gelation is promoted by heating the solution up to 40-110°C, preferably 40-80°C.
  • the present disclosure relates to a new soft gel material, prepared through the gelation of ionic liquids using unprotected tripeptides.
  • the rationale to design the tripeptide ionogel formulations and respective production methods started by understanding the gelation trigger and gelation protocols of previously described unprotected tripeptide hydrogelators.
  • the gelation trigger includes, for example, changes in pH, ionic strength or temperature [7-9]. Once the gelation trigger was understood, the ionic liquids were designed to mimic this trigger. Also, the ionogel production protocols were designed accordingly. With this approach, the aqueous solvent of the hydrogels was totally or partially substituted by rationally designed ionic liquids.
  • KYF has also shown the capability to form hydrogels when dissolved in other aqueous solvents such as sodium chloride (5 mM), addition of sodium hydroxide (1 M) for the final pH value, or sodium phosphate buffer solution 0.1 M pH 8 (Table 1), but only when the pH value is in the range of 7.5 ⁇ 1.0. KFF did not self-assembly in sodium phosphate buffer (0.1 M pH 8.0). Table 1: System I hydrogels, tripeptide hydrogelation triggered by pH.
  • DFY-NH 2 was also able to form a transparent gel when dissolved by heat in 0.2 M Citrate-0.1 M Phosphate buffer pH 7.0. However, this tripeptide precipitates when the solvent is 0.1 M Citrate buffer pH 6.2. In System II, the gelation trigger seems to be mainly phosphate dependent. Table 2: System II hydrogels, tripeptide hydrogelation triggered by buffer composition and temperature.
  • Solvent Gelator RFF DFY-NH 2 YFD-NH 2 Deionized water (+NaOH)* Solution Insoluble Not tested 0.1 M Sodium phosphate buffer, pH 8.0 Gel (30 mM) Gel (20 mM) Gel (20 mM) 0.1 M Glycine-NaOH buffer pH 8.6 Solution Not tested Not tested Not tested 0.2 M Citrate -0.1 M Phosphate buffer pH 7.0 Gel (30 mM) Not tested Not tested 0.1M Citrate buffer pH 6.2 Precipitate (30 mM) Not tested Not tested * Add NaOH (1M) to raise the pH to 7.5 ⁇ 1. Figures in parenthesis are gelation concentrations.
  • the imidazolium-based ionic liquids can be selected from a list comprising 1-butyl-3-methylimidazolium dicyanamide ([Bmim][DCA]), 1-ethyl-3-methylimidazolium dicyanamide ([Emim][DCA]), 1-butyl-3-methylimidazolium chloride ([Bmim][CI]), 1-ethyl-3-methylimidazolium chloride ([Emim][CI]), or mixtures thereof.
  • the choline phosphate buffer is an ionic liquid buffer system formed by the mixture of two ionic liquids (i) choline dihydrogenphosphate and (ii) dicholine monohydrogen phosphate in equimolar amounts, to which 16-17% (w/w) deionized water are added.
  • the pH of the choline phosphate buffer is 7.1 ⁇ 1.0, and is called the apparent pH ( Figure 11 ).
  • Imidazolium-based ionic liquids are defined as those where the cation is a charged heterocycle organic molecule, an imidazole ring where one of the nitrogen atoms is protonated such as dialkylimidazolium.
  • ammonium-based ionic liquids are composed by an ammonium cation, a positively charged or protonated amine or a quaternary ammonium cation of the basic structure NR 4 + , where one or more hydrogen atoms can be replaced by alkyl groups and/or alkyl groups with hydroxy group attached (R).
  • an alkylammonium As example an alkylammonium.
  • tripeptides KYF and KFF were dissolved in ionic liquids at a given concentration in a glass vial at room temperature (18-27°C), by means of vortex and sonication, followed by pH increasing to 7.5 ⁇ 1, by dropwise addition of alkaline solutions, such as, sodium hydroxide (1 M or 2 M), potassium hydroxide, [Bmim][OH], or choline hydroxide.
  • alkaline solutions such as, sodium hydroxide (1 M or 2 M), potassium hydroxide, [Bmim][OH], or choline hydroxide.
  • KYF and KFF were ionogelators.
  • KYF and KFF tripeptides when dissolved in ionic liquids of imidazolium-family, [Bmim][DCA], [Bmim][CI], [Emim][DCA] and [Emim][CI], and after rising the pH to 7.5 ⁇ 1.0 (by the addition of NaOH solutions (1 M, 2 M), [Bmim][OH] or choline hydroxide), formed self-supporting gels ( Figures 3 and 6 ).
  • the gelator KYF formed a transparent and clear gel when dissolved in [Bmim][DCA] and in [Emim][DCA] ( Figure 3 ).
  • the molecular self-assembly occurred at 412 mM, a high gelation concentration when compared with the one needed for a hydrogel formation (20 mM) (Table 1).
  • the tripeptide KFF formed opaque gels with self-assembled structures with birefringence properties when dissolved in [Bmim][DCA] and [Emim][DCA] and after rising the pH to 7.5 ⁇ 1.0 (by the addition of NaOH solutions (1 M, 2 M), [Bmim][OH] or choline hydroxide).
  • the formation of self-assembled structures with birefringence properties was observed in real-time by optical microscopy ( Figures 7 and 8 ) in a similar process to the one described by Wang et al.[20]. With time, the opaque gels, containing the birefringent structures, changed to transparent clear gels, suggesting the 'evolution' to fibrillary structures ( Figure 8 ).
  • the gelation trigger seems to be phosphate dependent.
  • the aqueous solvent was mimicked by an ionic liquid buffer system, the choline phosphate buffer [21].
  • the ionic liquid buffer with an apparent pH of 7.1 ⁇ 1, has a water content of 16% - 17% (characterization performed by Karl Fischer) ( Figure 11 ).
  • RFF and DFY-NH 2 tripeptides formed self-supported gels when dissolved in choline phosphate buffer at concentrations of 30mM and 45mM, respectively.
  • the tripeptide RFF formed an opaque gel with self-assembly microstructures, while the gelator DFY-NH 2 was capable of forming a transparent clear gel ( Figure 12 ). It is noteworthy that, depending on the batch used, the gelation time for DFY-NH 2 in choline phosphate buffer was much faster than for the corresponding hydrogel (observed for the tripeptide batch within counter ion chloride), occurring instantaneously.
  • Choline phosphate buffer is composed by choline dihydrogenphosphate and dicholine monohydrogenphosphate (equimolar amounts) and 16-17% (w/w) deionized water. Figures in parenthesis are gelation concentrations.
  • Tripeptide ionogels of both systems, I and II were characterized by several techniques.
  • self-supporting hydrogels and ionogels can be checked visually by the glass vial inversion test.
  • the macroscopic manifestation of successful gelation is the absence of observable material flow in the vials wall upon inversion of the glass vial. Examples are shown in Figures 3 , 4 , 6 and 8 for system I, and in Figure 12-14 and 20 for system II.
  • Gel-like properties of biomaterials can also but determined through rheological measurements.
  • the rheological properties of DFY-NH 2 gels (system II) were measured with an Anton Paar MCR 302 rheometer with the temperature controlled at 25°C using a parallel sandblasted 10 mm plate. Amplitude sweep was performed to determine the critical strain. Frequency sweep was performed to measure G' and G" at a constant strain (0.5 and/or 0.1), in the angular frequency range 0.1-100 rad/s. The experiments were carried out approximately 24h after ionogel sample cooling.
  • the values of the storage modulus (G') were about three to four times higher than the loss modulus (G") over the entire angular frequency range (0.1-100 rad/s) at 25oC indicating that 30 mM DFY-NH 2 ionogel exhibited gel-like characteristics.
  • the results obtained from ionogel's characterization can be seen in Figure 16 .
  • ATR-FTIR total reflection Fourier transform infrared
  • ATR-FTIR spectra obtained for KYF in [Bmim][DCA], KYF in [Emim][DCA], KFF in [Bmim][DCA] and KFF in [Emim][DCA] showed peak formation in amide I region for tripeptide ionogels ( Figure 9 ).
  • the results suggested different interactions, and consequently self-assembly for KYF and KFF in ionic liquids as macroscopic and microscopically observed.
  • the peak observed at 1672 cm -1 is due to the presence of trifluoroacetic acid in the tripeptide sample.
  • DFY-NH 2 ionogel, DFY-NH 2 hydrogel and YFD-NH 2 hydrogel have shown peaks in the amide I region which may suggest periodical organization either through helical or ⁇ -sheet structures ( Figure 15 ).
  • the morphology of the gels was characterized by microscopy.
  • the gels were characterized by different microscopy analysis, namely optical and polarised microscopy and by transmission electron microscopy (TEM).
  • TEM transmission electron microscopy
  • KFF ionogel (system I) samples were observed by optical microscopy using a microscope Zeiss Axio Observer.Z1/7 coupled with an Axiocam 503 color camera equipped with crossed polarizers.
  • Microscope images showed the formation of birefringent microstructures associated to the self-assembly of KFF in [Bmim][DCA] or [Emim][DCA]. These microstructures are only observed for opaque gel and not for translucid KFF ionogels. Examples are shown in figures 7 and 8 .
  • DFY-NH 2 ionogel (system II) nanostructures were characterized by TEM.
  • carbon-coated grids were purchased from Electron Microscopy Sciences. In an embodiment, a drop (5 ⁇ l) of the sample solution was applied to the carbon-coated grid and incubated for one minute.
  • the sample was then washed with water to remove ionic liquids and then stained with 5 ⁇ l of 2% (w/v) uranyl acetate solution for 30 seconds. After blotting the excess stain solution, the grid was left to air dry.
  • the negatively stained sample was imaged in a FEI TITAN Halo TEM operating at 300kV. Images were recorded in the low-dose mode (20e - ⁇ -2 ) on a FEI CETA 16M camera (4096 x 4096 pixels). DFY-NH 2 ionogels showed a dense three-dimensional nanofibrous network as can be seen of Figure 17 . The average diameter of the individual fibers was about 8-12 nm.
  • the ionic conductivity of ionogels was measured by electrochemical impedance spectroscopy at environmental conditions (temperature 18-27°C, atmospheric pressure (1013.25hPa), and RH 30-80%), covering a frequency range from 100 kHz to 0.1 Hz.
  • ionic conductivity of DFY-NH 2 ionogel (System II) was 1.0 ⁇ 10 -3 S.cm -1 , very similar to the one exhibited by its solvent choline phosphate buffer ( Figure 18 ).
  • ionogel formation does not affect the ionic conductivity of the ionic liquids and the same value ranges were observed in the corresponding ionogels (for example, at 1 kHz for [Emim][DCA] 18 ⁇ 10 -1 S.cm -1 , for [Bmim][DCA] 10 ⁇ 10 -1 S.cm -1 and for dicholine monohydrogenphosphate_citric acid (1:1) 4.7 ⁇ 10 -5 S.cm -1 ).
  • Conductive properties of the tripeptide ionogels (Systems I and II) were shown by lightening up light-emitting diodes (LED) as shown in Figures 10 (System I) and 22 (System II). It was observed that the LED lights up when using the tripeptide ionogels, independently of its water content.
  • thermoreversibility of tripeptide ionogels is illustrated in Figure 20 .
  • obtained ionogels were heated to 75 ⁇ 35°C for 10 minutes. Afterwards, they were left to cool down to room temperature (18-25°C). The gels were observed by the glass vial inversion test before heating, after heating and after cooling down. This is shown to System II tripeptides but the same is observed for System I.
  • Figure 21 illustrates an embodiment of the potential of the ionogel formulations to be spread as thin films on a substrate (here for example spread on an unmodified glass slide). This Figure 21 also shows the self-healing properties of tripeptide ionogels.
  • Figures 5 and 19 it is possible to see the processing of the tripeptide ionogel macroscopic structures, moulded by casting the formulation in a 3D printed mould.
  • tripeptide ionogels As gas and volatile organic compound sensing materials used in devices was explored. Variations on the electric properties of tripeptides ionogels were observed according with the concentration of an exposed volatile compound. As an example, thin films of 50mM DFY-NH 2 ionogels, previously film-coated into gold-patterned electrodes glass substrates, were exposed to different humidity rates. A schematic representation of the in-house built electronics and results can be seen in Figure 23 . This application is shown to tripeptide ionogels of system II but the same is observed for system I tripeptide ionogels.
  • the addition of the tripeptide and ionic liquid is made in defined orders and concentrations, at specific conditions of pH, temperature, sonication and agitation, and with added additives when required.
  • the pH of the tripeptide dissolved in the ionic liquid is increased by the addition of NaOH, KOH, [Bmim][OH], or choline hydroxide.
  • an additive capable of hydrogen bonding can be citric acid, tartaric acid, ascorbic acid, glucose, sucrose, xylose, arginine, histidine, proline, urea, sorbitol, xylitol, glycerol, monoethylene glycol, menthol, lactic acid, betain, or mixtures thereof.
  • the final tripeptide ionogels contain variable amounts of water (always below the 90% (w/w) threshold value found in hydrogels; typically, in tripeptide ionogels the water content is found between 2-75%).
  • the formulations and respective tripeptide ionogels can be processed by diverse techniques and moulded into different formats, yielding advanced functional materials.
  • the formed supramolecular structures can be processed in different geometries selected from discs, films, fibers, spheres, cubes, mesh, channels or patterned structures, using different methods as moulding, casting, spin coating, film coating, spinning, electrospinning, microfluidics, 3D-printing, ink-jet printing, patterning, metal depositions and fabrication methods. They can be casted into several substrates such as glass slides, silicon wafers, interdigitated electrodes, with or without chemical or physical modification.
  • the tripeptide ionogels are stable at ambient conditions, have thermal, electrochemical and chemical stability in a wide range of temperature and humidity conditions, are conducting, soft, self-healing, thermoreversible, have a large electrochemical window, are non-flammable, non-toxic, biocompatible and biodegradable materials.
  • the ionogels are stimuli-responsive. They possess electric, ionic and/or protonic conductivity. They possess optical and piezoelectric properties. The conductivity, optical and piezoelectricity changes when in presence of chemical (e.g. analytes in gas or aqueous phases, cells) or physical stimuli (e.g. temperature, pressure) can be used as transducing signals to develop sensors.
  • chemical e.g. analytes in gas or aqueous phases, cells
  • physical stimuli e.g. temperature, pressure
  • the tripeptide ionogels may find application in a variety of technological fields, such as sensing devices; electronic devices; opto-electronic devices; flexible and wearable devices; conducting devices; materials for additive manufacturing; chemocatalysis and biocatalysis; coating materials; metal recovery; encapsulation, drug delivery and/or cell assays; pharmaceutical formulations; electrochemical devices such batteries, capacitors and solar cells; electrolytes; semi-solid lubricants; magnetorheological fluids and electrochemical devices; adsorbents; purification matrices; food; and cosmetics products.
  • Unprotected tripeptides KYF, KFF, RFF, DFY-NH 2 and YFD-NH 2 were produced in-house by conventional peptide synthesis methods or obtained from commercial suppliers.
  • the ionic liquids used were purchased to IoLiTec (Germany).
  • the water content of all ionic liquids used was determined by Karl-Fischer titration using an 831 KF Coulometer with a generator electrode without diaphragm with Hydranal Coulomat AG as the analyte. The final value noted was the average of a minimum of three experiments.
  • the tripeptide KYF was dissolved in 1-butyl-3-methyl imidazolium dicyanamide (water content estimated by Karl Fisher as 0.5 ⁇ 0.5% (w/w)) by vortex and sonication, followed by increasing the pH to 7.5 ⁇ 1 by dropwise addition of sodium hydroxide solution (NaOH) 2 M.
  • the final peptide concentration range in the ionogel was ideally between 50 - 550 mM, with 2-72% (w/w) water.
  • KYF ionogel can also be prepared in 1-ethyl-3-methylimidazolium dicyanamide (water content estimated by Karl Fisher as 0.5 ⁇ 0.5%(w/w)) following the experimental protocol described above, yielding a final peptide concentration ideally between 50-500 mM, with 2-72% (w/w) water. All characterization of the gels took place at least 24 hours after ionogel preparation. Samples for ATR-FTIR analysis were prepared with NaOD solution instead of NaOH. As an alternative, 1-butyl-3-methyl imidazolium chloride or 1-ethyl-3-methylimidazolium chloride can be used to prepare the ionogels. Examples of KYF ionogels or related characterization can be seen in Figures 3 - 5 , 9 , 10 and 24 .
  • KFF was dissolved in 1-butyl-3-methyl imidazolium dicyanamide (water content estimated by Karl Fisher as 0.5 ⁇ 0.5% (w/w)) by vortex and sonication, followed by increasing the pH to 7.5 ⁇ 1 by dropwise addition of sodium hydroxide solution (NaOH) 2M.
  • NaOH sodium hydroxide solution
  • the final peptide concentration in the ionogel was ideally between 50-200 mM, with 2-75% (w/w) water.
  • KFF ionogel can also be prepared in 1-ethyl-3-methylimidazolium dicyanamide (water content estimated by Karl Fisher as 0.5 ⁇ 0.5% (w/w)) following the experimental protocol described above, yielding a final peptide concentration ideally between 50-500 mM, with 2-75% (w/w) water. Characterization of the gels took place at least 24 hours after ionogel preparation. Samples for ATR-FTIR analysis were prepared using NaOD solution instead of NaOH. As an alternative, 1-butyl-3-methyl imidazolium chloride or 1-ethyl-3-methylimidazolium chloride can be used to prepare the ionogels. Examples of KFF ionogels or related characterization can be seen in Figures 6 - 9 , 24 .
  • the choline phosphate ionic liquid buffer system is an ionic liquid hydrated buffer formed by the mixture of two ionic liquids (i) choline dihydrogenphosphate and (ii) dicholine monohydrogenphosphate in equimolar amounts, to which 16-17% (w/w) deionized water are added.
  • the buffer is homogenized by means of vortex and sonication.
  • Ionic liquid buffer water content was determined using a Karl Fischer; apparent pH was verified to be at 7.1 ⁇ 1. Chemical structures of choline dihydrogenphosphate and dicholine monohydrogenphosphate are presented in Figure 11 .
  • DFY-NH 2 was dissolved in choline phosphate buffer (apparent pH 7.1 ⁇ 1, 16%-17% (w/w) water content) heating at 75 ⁇ 35 °C following by vortex and cooling down to room temperature, or just cooling down to room temperature.
  • the final peptide concentration ideally is between 20-100 mM, with 16-20 % (w/w) water. Characterization of the gels took place at least 24 hours after ionogel preparation. Samples for ATR-FTIR analysis, choline phosphate buffer was prepared using D 2 O instead of H 2 O. Examples of DFY-NH 2 ionogels or related characterization can be seen in Figures 12 and 14-23 .
  • RFF was dissolved in choline phosphate buffer (apparent pH 7.1 ⁇ 1, 16%-17% (w/w) water content) heating at 75 ⁇ 35 oC following by cooling to room temperature.
  • the final peptide concentration in the ionogel ideally is between 20-100 mM, with 16-20 % (w/w) water. Characterization of the gels took place at least 24 hours after ionogel preparation.
  • Samples for ATR-FTIR analysis, choline phosphate buffer was prepared using D 2 O instead of H 2 O. Examples of RFF ionogels can be seen in Figures 12 , 13 .
  • RFF ionogel was prepared by heating and stirring method. This method consist in mixing the components of the gel: (i) ammonium quaternary salt: choline dihydrogenphosphate, dicholine monohydrogenphosphate or choline chloride (ii) an additive which has the capability of H-bond donor or receptor, such as citric acid, and (iii) an unprotected tripeptide, RFF according with the amounts calculated considering different molar ratios preferentially 1:1:0.5 - 1:1:0.005, ideally 1:1:0.1 - 1:1:0.005. The system was heated to 80 ⁇ 20oC and stirred at 300 rpm, until a clear transparent viscous solution or gel is obtained. Examples of RFF ionogels with additive can be seen in Figure 12 .
  • the ionic liquid 1-butyl-3-methyl imidazolium dicyanamide (water content estimated by Karl Fisher as 0.5 ⁇ 0.5%) and the liquid crystal 5CB (4-Cyano-4'-pentyibiphenyl) were mixed by magnetic stirring at 300rpm.
  • the tripeptide KYF or tripeptide KFF was added to the mixture following by increasing the pH to 7.5 ⁇ 1 by dropwise addition of sodium hydroxide solution (NaOH) 1M. Examples are shown in Figure 24 .
  • Liquid/viscous samples were prepared by pipetting 100 ⁇ l of the solution into an 0.5 ml Eppendorf previously fill with 100 ⁇ l PDMS in order to decrease the amount of biomaterial need for the characterization.
  • the gold coated electrodes (connection pines) were inserted in an in-house 3D printed adapter and position in the Eppendorf being partially submersed in the biomaterial.
  • Gel samples were prepared using an in-house 3D printed o-ring with 6mm inner diameter and 0.6mm height. The system, ring - hydrogel, was sandwiched between two gold contacts.
  • the results of ionic conductivity studies for 30 mM DFY-NH 2 ionogel in choline phosphate buffer are shown in Figure 18 .
  • Figures 10 and 22 demonstrate the ion conduction of the tripeptide ionogel by lightening up a light-emitting diode (LED).
  • LED light-emitting diode
  • Triplicates of DFY-NH 2 ionogel thin films were placed in the detection chamber of an associated in-house electronic nose ( Figure 23A ) and exposed to five humidification (the thin films were exposed to humidified nitrogen for 140s at 1.5slpm) and drying (the thin films were exposed to dry nitrogen for 140s at 1.5 slpm) periods, for four different RH levels (58%, 50%, 44%, 25%).
  • the RH levels were generated by bubbling a nitrogen stream, control by a mass flow controller (MFC, MC-5SLPM-D/5M, Alicat Scientific Inc.) at 1.5slpm, in the different supersaturated salt solutions (distilled water, sodium chloride, sodium bromide and magnesium chloride) before entering the detection chamber.
  • MFC mass flow controller
  • a humidity sensor was placed in the outlet of the detection chamber, in order to measure the variations of RH applied to the ionogel thin films when they are exposed alternately to humid and dry nitrogen. The results are shown in Figure 23 . Similar results were obtained when exposing the thin films to volatile organic compounds.
  • the project leading to this invention has received funding from the European Research Council through the grant reference SCENT-ERC-2014-STG-639123 and from Fundaç ⁇ o para a Ciência e Tecnologia through the PhD scholarship SFRH/BD/113112/2015.

Landscapes

  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Claims (15)

  1. Une composition d'ionogel comprenant :
    au moins un liquide ionique choisi parmi un liquide ionique d'imidazolium, des liquides ioniques à base d'ammonium, ou des mélanges de ceux-ci ; et
    au moins un tripeptide non protégé en tant que gélifiant, dans lequel le tripeptide est choisi parmi la liste suivante : Lysine-Tyrosine-Phénylalanine, Lysine-Phénylalanine-Phénylalanine, Arginine-Phénylalanine-Phénylalanine, Acide aspartique-Phénylalanine-Tyrosine, et Tyrosine-Phénylalanine-Acide aspartique ; ou
    10-700 mM, préférablement 20 - 600 mM, d'au moins un tripeptide non protégé en tant que gélifiant, dans laquelle le tripeptide non protégé comprend au moins une phénylalanine.
  2. L'ionogel selon la revendication précédente dans lequel les tripeptides non protégés ont un amide dans la C-terminale, préférablement les tripeptides Acide aspartique-Phénylalanine-Tyrosine et Tyrosine-Phénylalanine-Acide aspartique.
  3. L'ionogel selon l'une quelconque des revendications précédentes dans lequel les tripeptides non protégés ont un poids moléculaire inférieur ou égal à 2000 g/mol, préférablement situé entre 270 et 540 g/mol.
  4. L'ionogel selon l'une quelconque des revendications précédentes dans lequel les concentrations de liquide ionique varient entre 20 et 98% (p/p).
  5. L'ionogel selon l'une quelconque des revendications précédentes, dans lequel le liquide ionique est choisi parmi des liquides ioniques contenant du phosphate, des liquides ioniques contenant du chlorure, des liquides ioniques contenant du dicyanamide, des sels d'ammonium quaternaire, ou des mélanges de ceux-ci.
  6. L'ionogel selon l'une quelconque des revendications précédentes dans lequel les liquides ioniques à base d'imidazolium sont choisis parmi une liste comprenant les éléments suivants: dicyanamide de 1-butyl-3-méthylimidazolium, dicyanamide de 1-éthyl-3-méthylimidazolium, chlorure de 1-butyl-3-méthylimidazolium, chlorure de 1-éthyl-3-méthylimidazolium, ou des mélanges de ceux-ci, ou dans lequel les liquides ioniques à base d'ammonium sont choisis parmi une liste comprenant les éléments suivants: chlorure de choline, hydroxyde de choline, tampon de phosphate de choline, formiate de 2-hydroxyéthylammonium, dihydrogénophosphate de choline, monohydrogénophosphate de dicholine, ou des mélanges de ceux-ci.
  7. L'ionogel selon l'une quelconque des revendications précédentes dans lequel l'hydrogélation des tripeptides est déclenchée par des changements de température, de solution tampon ou de pH, préférablement en augmentant le pH jusqu'à 7-7,5, dans lequel le pH est augmenté en ajoutant de l'hydroxyde de sodium, de l'hydroxyde de choline ou de l'hydroxyde de 1-butyl-3-méthylimidazolium.
  8. L'ionogel selon l'une quelconque des revendications précédentes comprenant également un additif choisi parmi la liste suivante : acide citrique, acide tartrique, acide ascorbique, glucose, sucrose, xylose, arginine, histidine, proline, urée, sorbitol, xylitol, glycérol, monoéthylène glycol, menthol, acide lactique, bétaïne, ou des mélanges de ceux-ci.
  9. L'ionogel selon la revendication précédente dans lequel le rapport molaire entre le liquide ionique et l'additif varie entre 1:1 et 1:10, préférablement entre 1:1 et 1:2.
  10. L'ionogel selon l'une quelconque des revendications précédentes dans lequel l'ionogel est mou, auto-curable, thermoréversible, sensible aux stimulus, non inflammable, non toxique, biocompatible et biodégradable.
  11. L'ionogel selon l'une quelconque des revendications précédentes comprenant également un composant sensible aux stimulus, le composant sensible aux stimulus étant préférablement un cristal liquide.
  12. L'ionogel selon l'une quelconque des revendications précédentes pouvant être obtenu par procédé de moulage, coulage, revêtement par centrifugation, revêtement par pellicule, centrifugation, électrofilage, microfluidique, impression 3D, impression par jet d'encre, structuration ou dépôt de métal.
  13. Disque, pellicule, fibre, sphère, cube, maillage, canal ou structure à dessin comprenant la composition d'ionogel décrite dans l'une quelconque des revendications précédentes.
  14. Un article comprenant la composition d'ionogel décrite dans l'une quelconque des revendications précédentes, préférablement dans lequel l'article est un dispositif capteur, un dispositif électronique, un dispositif opto-électronique, un dispositif flexible, un dispositif portable, un dispositif conducteur, un matériau de revêtement, un dispositif électrochimique, un électrolyte, un lubrifiant semi-solide, un agent absorbant, une formulation pharmaceutique, un produit alimentaire, ou un produit cosmétique.
  15. Kit ou réactif comprenant la composition d'ionogel décrite dans l'une quelconque des revendications précédentes.
EP20732663.8A 2019-05-20 2020-05-20 Composition d'ionogel peptidique, procédés et utilisations de celle-ci Active EP3973550B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PT11552419 2019-05-20
PT11552819 2019-05-20
PT11552319 2019-05-20
PCT/IB2020/054794 WO2020234806A1 (fr) 2019-05-20 2020-05-20 Composition d'ionogel peptidique, procédés et utilisations de celle-ci

Publications (3)

Publication Number Publication Date
EP3973550A1 EP3973550A1 (fr) 2022-03-30
EP3973550C0 EP3973550C0 (fr) 2024-01-31
EP3973550B1 true EP3973550B1 (fr) 2024-01-31

Family

ID=71092564

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20732663.8A Active EP3973550B1 (fr) 2019-05-20 2020-05-20 Composition d'ionogel peptidique, procédés et utilisations de celle-ci

Country Status (2)

Country Link
EP (1) EP3973550B1 (fr)
WO (1) WO2020234806A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114716342A (zh) * 2022-04-02 2022-07-08 江苏尊绅科技有限公司 N-胺烷基取代双葡萄糖酰胺及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955434A (en) 1995-02-09 1999-09-21 Brigham & Women's Hospital Gel-forming polypeptide derivatives
AU2003286404A1 (en) 2002-12-09 2004-06-30 Ramot At Tel Aviv University Ltd. Peptide nanostructures, methods for their preparation and use
WO2008097300A2 (fr) 2007-02-08 2008-08-14 Regents Of The University Of Minnesota Gels ioniques et dispositifs électroniques utilisant des gels ioniques
EP2609066A4 (fr) 2010-08-26 2015-03-25 Univ Georgetown Gélifiants de faible poids moléculaire pour confiner les déversements accidentels de pétrole brut, de produits pétroliers ou agents chimiques
WO2016055810A1 (fr) 2014-10-09 2016-04-14 University Of Strathclyde Tripeptides à auto-agrégation
US10343144B2 (en) 2015-05-29 2019-07-09 Hindustan Petroleum Corporation Ltd. Molecular gelators for containing oil spillage
EP3414258A1 (fr) 2016-02-12 2018-12-19 Hindustan Petroleum Corporation Ltd. Agents de gélification moléculaire et leurs utilisations
CN110325204B (zh) 2016-09-09 2023-11-07 纽约城市大学研究基金会 自组装的肽聚合物

Also Published As

Publication number Publication date
WO2020234806A1 (fr) 2020-11-26
EP3973550C0 (fr) 2024-01-31
EP3973550A1 (fr) 2022-03-30

Similar Documents

Publication Publication Date Title
Fan et al. Ionogels: recent advances in design, material properties and emerging biomedical applications
Friggeri et al. Charge-transfer phenomena in novel, dual-component, sugar-based organogels
Boettcher et al. Comparative cryo-electron microscopy of noncovalent N-dodecanoyl-(D-and L-) serine assemblies in vitreous toluene and water
Ferrari et al. Solvent and substrate contributions to the formation of breath figure patterns in polystyrene films
Buijnsters et al. Oriented crystallization of calcium carbonate under self-organized monolayers of amide-containing phospholipids
Bhattacharya et al. Impressive gelation in organic solvents by synthetic, low molecular mass, self-organizing urethane amides of L-phenylalanine
EP3973550B1 (fr) Composition d'ionogel peptidique, procédés et utilisations de celle-ci
Geng et al. Low-molecular-weight organo-and hydrogelators based on cyclo (L-Lys-L-Glu)
Jang et al. Dendritic physical gels: structural parameters for gelation with peptide-core dendrimers
Leick et al. Mechanical properties of liquid-filled shellac composite capsules
Feng et al. Investigation of the relationships between the thermodynamic phase behavior and gelation behavior of a series of tripodal trisamide compounds
US10695282B2 (en) Functionalized transition metal dichalcogenides and composition for antioxidation containing the same
JP6698325B2 (ja) 超分子金属−有機構造体物質およびその製造方法
Yan et al. Towards Large‐Scale Fabrication of Self‐Healable Functional Hydrogel Coatings for Anti‐Fog/Frost Surfaces and Flexible Sensors
Wang et al. Investigation on the assembled structure–property correlation of supramolecular hydrogel formed from low-molecular-weight gelator
KR20020019913A (ko) 단백질의 빠른 탈수법
Puiggalí-Jou et al. Confinement of a β-barrel protein in nanoperforated free-standing nanomembranes for ion transport
Moreira et al. Synergy between silk fibroin and ionic liquids for active gas-sensing materials
Liang et al. Petunia-shaped superstructures of CaCO3 aggregates modulated by modified chitosan
Yan et al. Characterization and bacterial response of zinc oxide particles prepared by a biomineralization process
Brizard et al. Self-assembled interpenetrating networks by orthogonal self assembly of surfactants and hydrogelators
Maji et al. Mueller matrix fluorescence spectroscopy for probing self-assembled peptide-based hybrid supramolecular structure and orientation
Bieser et al. Structure and properties of an exceptional low molecular weight hydrogelator
van der Wal et al. Impedance spectroscopy and surface study of potassium-selective silicone rubber membranes
CN105777816A (zh) 一种超分子水凝胶因子、超分子水凝胶及其制备方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20221123

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20230508

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602020024997

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20240228

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI

Effective date: 20240306

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240531

U20 Renewal fee paid [unitary effect]

Year of fee payment: 5

Effective date: 20240603

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240131

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240430

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240430

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240531

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240131

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240501

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240131